Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Informed Consent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,960 result(s) found for: Informed Consent. Displaying page 714 of 1,448.
    «« First « Previous 710  711  712  713  714  715  716  717  718  Next» Last»»
    EudraCT Number: 2019-005005-43 Sponsor Protocol Number: FACEII Start Date*: 2022-06-06
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona
    Full Title: Ferinject in Addition to pulmonary rehabilitation in patients with COPD and iron deficiency to improve Exercise tolerance (FACE II study)
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005111-16 Sponsor Protocol Number: XP-IIT-0029 Start Date*: 2015-02-16
    Sponsor Name:Instituto de Investigaciones del Sueño
    Full Title: Response to gabapentin enacarbil in two groups of RLS patients: Previously exposed to long-term treatment with dopaminergic agents versus dopaminergic treatment-naive patients.
    Medical condition: RLS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004285-13 Sponsor Protocol Number: 1042-0500 Start Date*: 2007-05-11
    Sponsor Name:Marinus Pharmaceuticals, Inc.
    Full Title: A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms.
    Medical condition: Infantile spasms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021750 Infantile spasms LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-000474-38 Sponsor Protocol Number: ZX008-1504 Start Date*: 2016-09-13
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), ...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001887-46 Sponsor Protocol Number: STH18493 Start Date*: 2018-11-08
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD)
    Medical condition: Parkinson’s disease (PD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-000285-30 Sponsor Protocol Number: TMC114IFD3001 Start Date*: 2018-01-03
    Sponsor Name:Janssen Research and Development
    Full Title: Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected adults, adolescents and children aged 3 years and above.
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005057-39 Sponsor Protocol Number: ZPL389/101 Start Date*: 2015-04-10
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFECTS OF 8 WEEKS TREATMENT WITH ORAL ZPL-3893787 (30 MG OD X 56 DAYS) ON PRURITUS IN ADULT SUBJECTS WITH MODE...
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005298-19 Sponsor Protocol Number: LUD2015-005 Start Date*: 2016-03-08
    Sponsor Name:Ludwig Institute for Cancer Research Ltd.
    Full Title: Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer
    Medical condition: Oesophageal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026180 Malignant neoplasm of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001820-22 Sponsor Protocol Number: Sci-B-Vac–002 Start Date*: 2018-02-20
    Sponsor Name:VBI Vaccines INC.
    Full Title: A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
    Medical condition: Hepatitis B Vaccination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10054181 Hepatitis B immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002777-29 Sponsor Protocol Number: M17-377 Start Date*: 2022-10-14
    Sponsor Name:AbbVie Inc
    Full Title: A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects in Japan with Moderate to S...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002801-36 Sponsor Protocol Number: Can-201 Start Date*: 2023-03-08
    Sponsor Name:Cantex Pharmaceuticals Inc.
    Full Title: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly...
    Medical condition: Newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004458-41 Sponsor Protocol Number: D-001-01 Start Date*: 2018-10-04
    Sponsor Name:Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult pa...
    Medical condition: chronic spontaneous urticaria despite H1-antihistamine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002721-29 Sponsor Protocol Number: 08486 Start Date*: 2018-12-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy
    Medical condition: Mitochondrial Myopathy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-002933-23 Sponsor Protocol Number: DAR-INT-14-01 Start Date*: 2016-05-24
    Sponsor Name:TRB CHEMEDICA INTERNATIONAL SA
    Full Title: AN INTERNATIONAL, MULTICENTRE, DOUBLE-BLIND, RANDOMISED STUDY OF THE EFFECT OF DIACEREIN VS CELECOXIB ON SYMPTOMS AND STRUCTURAL CHANGES IN SYMPTOMATIC KNEE OSTEOARTHRITIS PATIENTS AS ASSESSED BY M...
    Medical condition: Pain reduction in symptomatic knee osteoarthritis (OA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018839 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002357-35 Sponsor Protocol Number: SQ147214 Start Date*: 2015-09-22
    Sponsor Name:Research, Development & Innovation Department, UHCW NHS Trust
    Full Title: Anticoagulants for Living FoEtuses in women with recurrent miscarriage and inherited thrombophilia : ALIFE 2
    Medical condition: Inherited thrombophilia in recurrent miscarriage
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002877-20 Sponsor Protocol Number: C17-315-04 Start Date*: 2018-03-28
    Sponsor Name:Lytix Biopharma AS
    Full Title: An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma
    Medical condition: Soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072990 Soft tissue neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002093-42 Sponsor Protocol Number: SHP643-301 Start Date*: 2020-02-04
    Sponsor Name:Shire (Shire is now part of Takeda)
    Full Title: SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (...
    Medical condition: Hereditary Angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    23.1 10010331 - Congenital, familial and genetic disorders 10075280 Hereditary angioedema attack LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000867-65 Sponsor Protocol Number: C_30990_P1_06 Start Date*: 2021-04-19
    Sponsor Name:Luye Pharma Switzerland AG
    Full Title: Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease
    Medical condition: Idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005624-10 Sponsor Protocol Number: OVID-trial Start Date*: 2021-05-06
    Sponsor Name:University Hospital Zurich
    Full Title: ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL
    Medical condition: Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    22.1 10021881 - Infections and infestations 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004884-29 Sponsor Protocol Number: PSt012021 Start Date*: 2022-03-16
    Sponsor Name:Pharma Stulln GmbH
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Dose Finding Study of 0.05%, 0.025%, 0.01% and 0.005% Atropine Eye Drops to inhibit myopia progression in children in a European population
    Medical condition: Myopia progression in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 710  711  712  713  714  715  716  717  718  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 02:53:00 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA